Opsens Inc Gets a Buy Rating from RBC Capital

By Ryan Adsit

Opsens Inc (TSXV: OPS), the Consumer Goods sector company, was revisited by a Wall Street analyst on November 13. On November 13, analyst Douglas Miehm gave a Buy rating to OPS and set a C$2 price target.

According to TipRanks.com, Miehm is ranked 0 out of 5 stars with an average return of -11.1% and a 31.4% success rate. Miehm covers the Healthcare sector, focusing on stocks such as Achieve Life Sciences Inc, Novelion Therapeutics Inc, and Cardiome Pharma Corp.

Opsens Inc has an analyst consensus of Moderate Buy, with a price target consensus of C$2.

Opsens, Inc. engages in the development, manufacture, supply and installation of fiber optic systems for measuring pressure and temperature as well as other parameters. It operates under the Medical and Industrial segments. The Medical segment focuses mainly on the measure of Fractional Flow Reserve (FFR) in interventional cardiology.

The company’s shares closed on Tuesday at C$1.23.